<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37311658</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0560</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of cutaneous pathology</Title><ISOAbbreviation>J Cutan Pathol</ISOAbbreviation></Journal><ArticleTitle>A case of reactive granulomatous dermatitis associated with neonatal lupus erythematosus.</ArticleTitle><Pagination><StartPage>793</StartPage><EndPage>797</EndPage><MedlinePgn>793-797</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cup.14479</ELocationID><Abstract><AbstractText>Neonatal lupus erythematosus (NLE) is an uncommon disorder affecting approximately one out of 20&#x2009;000 live births in the United States. Common manifestations of NLE include cutaneous eruptions and cardiac involvement. The typical rash of NLE most closely resembles the rash of subacute cutaneous lupus erythematosus both clinically and histopathologically. We present a case of reactive granulomatous dermatitis (RGD) associated with NLE in a 3-month-old male in whom the initial histopathology and immunohistochemistry were concerning for hematologic malignancy. RGD is a unifying term used to describe cutaneous granulomatous eruptions that occur in response to a variety of stimuli, including autoimmune connective tissue diseases. Our case demonstrates the range of histopathological findings that may be present in the setting of NLE.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Cutaneous Pathology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Monica H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-2094-475X</Identifier><AffiliationInfo><Affiliation>University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onajin</LastName><ForeName>Oluwakemi</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-7602-2308</Identifier><AffiliationInfo><Affiliation>Section of Dermatology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkataraman</LastName><ForeName>Girish</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8674-2608</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Chicago Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0003-0221-6844</Identifier><AffiliationInfo><Affiliation>Section of Dermatology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cutan Pathol</MedlineTA><NlmUniqueID>0425124</NlmUniqueID><ISSNLinking>0303-6987</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536397">Neonatal Systemic lupus erythematosus</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003872" MajorTopicYN="Y">Dermatitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">histiocyte infiltration</Keyword><Keyword MajorTopicYN="N">neonatal lupus erythematosus</Keyword><Keyword MajorTopicYN="N">rash</Keyword><Keyword MajorTopicYN="N">reactive granulomatous dermatitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>21</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37311658</ArticleId><ArticleId IdType="doi">10.1111/cup.14479</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>University of Mansoura, Nasef N. Neonatal lupus erythematosus. Neonatol Clin Pediatr. 2014;1(1):1-10. doi:10.24966/NCP-878X/100002</Citation></Reference><Reference><Citation>Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al. Neonatal lupus erythematosus - practical guidelines. J Perinat Med. 2021;49(5):529-538. doi:10.1515/jpm-2020-0543</Citation></Reference><Reference><Citation>Zuppa AA, Riccardi R, Frezza S, et al. Neonatal lupus: follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmun Rev. 2017;16(4):427-432. doi:10.1016/j.autrev.2017.02.010</Citation></Reference><Reference><Citation>Vanoni F, Lava SAG, Fossali EF, et al. Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):469-476. doi:10.1007/s12016-017-8653-0</Citation></Reference><Reference><Citation>Wisuthsarewong W, Soongswang J, Chantorn R. Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatr Dermatol. 2011;28(2):115-121. doi:10.1111/j.1525-1470.2011.01300.x</Citation></Reference><Reference><Citation>Rosenbach M, English JC. Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification. Dermatol Clin. 2015;33(3):373-387. doi:10.1016/j.det.2015.03.005</Citation></Reference><Reference><Citation>Diaz-Frias J, Badri T. Neonatal lupus erythematosus. StatPearls. StatPearls Publishing; 2022 Accessed November 22, 2022. http://www.ncbi.nlm.nih.gov/books/NBK526061/</Citation></Reference><Reference><Citation>Romero Rey H, Avila-Alvarez A. Neonatal cutaneous lupus erythematosus. Arch Dis Child Fetal Neonatal Ed. 2019;104(2):F191. doi:10.1136/archdischild-2018-316147</Citation></Reference><Reference><Citation>Sitthinamsuwan P, Nitiyarom R, Chairatchaneeboon M, Wisuthsarewong W. Histiocytoid neutrophilic dermatitis, an unusual histopathology in neonatal lupus erythematosus. J Cutan Pathol. 2015;42(12):996-999. doi:10.1111/cup.12594</Citation></Reference><Reference><Citation>Okada N, Okuyama R, Uhara H. Marked histiocytic infiltration in neonatal lupus erythematosus. J Dermatol. 2014;41(2):192-193. doi:10.1111/1346-8138.12381</Citation></Reference><Reference><Citation>Coutinho I, Pereira N, Gouveia M, Cardoso JC, Tellechea O. Interstitial granulomatous dermatitis: a clinicopathological study. Am J Dermatopathol. 2015;37(8):614-619. doi:10.1097/DAD.0000000000000288</Citation></Reference><Reference><Citation>Akinshemoyin Vaughn OL, Siegel DH, Chiu YE, et al. Clinical and histologic presentation of pediatric reactive granulomatous dermatitis. Pediatr Dermatol. 2020;37(3):498-503. doi:10.1111/pde.14137</Citation></Reference><Reference><Citation>Kyriakou A, Patsatsi A, Papadopoulos V, Kioumi A, Efstratiou I, Lazaridou E. A case of palisaded neutrophilic granulomatous dermatitis with subsequent development of chronic myelomonocytic leukemia. Clin Case Rep. 2019;7(4):695-698. doi:10.1002/ccr3.2072</Citation></Reference><Reference><Citation>Silvestri F, Banavali S, Baccarani M, Preisler HD. The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. Haematologica. 1992;77(3):265-273.</Citation></Reference><Reference><Citation>Luskin MR, Huen AO, Brooks SA, et al. NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica. 2015;100(10):e412-e414. doi:10.3324/haematol.2015.129346</Citation></Reference><Reference><Citation>Terai S, Ueda-Hayakawa I, Nguyen CTH, et al. Palisaded neutrophilic and granulomatous dermatitis associated with systemic lupus erythematosus: possible involvement of CD163+ M2 macrophages in two cases, and a review of published works. Lupus. 2018;27(14):2220-2227. doi:10.1177/0961203318809892</Citation></Reference><Reference><Citation>Peroni A, Colato C, Schena D, Rongioletti F, Girolomoni G. Histiocytoid Sweet syndrome is infiltrated predominantly by M2-like macrophages. J Am Acad Dermatol. 2015;72(1):131-139. doi:10.1016/j.jaad.2014.09.025</Citation></Reference><Reference><Citation>Magro CM, Momtahen S, Nguyen GH, Wang X. Histiocytoid Sweet's syndrome: a localized cutaneous proliferation of macrophages frequently associated with chronic myeloproliferative disease. Eur J Dermatol. 2015;25(4):335-341. doi:10.1684/ejd.2015.2586</Citation></Reference><Reference><Citation>Sugioka K, Goto H, Sugita K, Habe K, Yamanaka K, Yamamoto O. Palisaded neutrophilic granulomatous dermatitis, interstitial granulomatous dermatitis and IgA vasculitis associated with incomplete Sj&#xf6;gren's syndrome. J Dermatol. 2021;48(4):556-558. doi:10.1111/1346-8138.15738</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>